Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Nuvectis Pharma, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma August 17, 2023, Fort Lee, NJ - Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration for the treatment of cholangiocarcinoma. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We are pleased to have received this designation from the FDA for NXP800, which emphasizes the need for new, innovative therapies for the treatment of cholangiocarcinoma, a deadly malignancy with only limited treatme..." |
|
| 08/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/03/2023 |
8-K
| Results of Operations and Financial Condition Interactive Data |
| 06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Nuvectis Pharma Announces FDA Clearance of NXP900 IND May 15, 2023, Fort Lee, NJ - Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration cleared the Company's Investigational New Drug Application for NXP900, which includes the Phase 1 clinical trial protocol. “The IND clearance by the FDA is a significant milestone for the NXP900 development program and for our overall corporate strategy, further demonstrating our ability to execute our business plan,” said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Mr. Bentsur continued, “Nuvectis now has two precision oncology, cl..." |
|
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results|
Docs:
|
"CONDENSED BALANCE SHEETS March 31, December 31, 2023 2022 Assets CURRENT ASSETS: Cash and cash equivalents $ 15,468 $ 19,993 Other current assets 740 412 TOTAL CURRENT ASSETS 16,208 20,405 TOTAL ASSETS $ 16,208 $ 20,405 Liabilities and Stockholders’ Equity CURRENT LIABILITIES Accounts payables $ 2,096 $ 2,910 Payable offering costs — 450 Accrued liabilities 156 445 Employee compensation and benefits 1,682 2,381 TOTAL CURRENT LIABILITIES 3,934 6,186 TOTAL LIABILITIES 3,934 6,186 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY: Common Stock, $0.00001 par value – 60,000,000 shares authorized as of March 31, 2023, and December 31, 2022, 15,886,139 and 15,190,720 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively * * Additional paid in capital 48,308 46,2..." |
|
| 04/03/2023 |
SC 13G
| Peters Thomas Phineas reports a 6.4% stake in Nuvectis Pharma, Inc. |
| 03/30/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/27/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/17/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/08/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"BALANCE SHEETS December 31, 2022 2021 Assets CURRENT ASSETS: Cash and cash equivalents 19,993 5,742 Other current assets 412 91 TOTAL CURRENT ASSETS 20,405 5,833 Deferred offering costs — 824 TOTAL ASSETS 20,405 6,657 Liabilities, Redeemable Convertible Preferred Shares and Stockholders' Equity CURRENT LIABILITIES Accounts payables 2,910 1,058 Payable offering costs 450 824 Accrued liabilities 445 395 Employee compensation and benefits 2,381 142 TOTAL CURRENT LIABILITIES 6,186 2,419 TOTAL LIABILITIES 6,186 2,419 COMMITMENTS AND CONTINGENCIES, see Note 3 REDEEMABLE CONVERTIBLE PREFERRED SHARES: Convertible preferred A stock, $0.00001 par value – Zero and 6,630,000 shares authorized as of December 31, 2022 and December 31, 2021, respectively. As of December 31, 2022 all issued and outstandin..." |
|
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/25/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/15/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 08/10/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/05/2022 |
8-K
| Quarterly results|
Docs:
|
"NUVECTIS PHARMA, INC. CONDENSED BALANCE SHEETS June 30, December 31, 2022 2021 Assets CURRENT ASSETS: Cash and cash equivalents 13,572 5,742 Other current assets 666 91 TOTAL CURRENT ASSETS 14,238 5,833 Deferred offering costs — 824 TOTAL ASSETS 14,238 6,657 Liabilities, Redeemable Convertible Preferred Shares and Stockholders’ Equity Accounts payables 1,434 1,058 Payable offering costs 341 824 Accrued liabilities 790 395 Employee compensation and benefits 173 142 TOTAL CURRENT LIABILITIES 2,738 2,419 TOTAL LIABILITIES 2,738 2,419 COMMITMENTS AND CONTINGENCIES, see Note 3 REDEEMABLE CONVERTIBLE PREFERRED SHARES: Convertible preferred A stock, $0.00001 par value – Zero and 6,630,000 shares authorized as of June 30, 2022 and December 31, 2021, respectively. As of June 30, 2022 all issued an..." |
|
| 07/29/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of July 27, 2022, between Nuvectis Pharma, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and/or Rule 506 of Regulation D promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Co...",
"PREFERRED INVESTMENT OPTION Nuvectis Pharma, Inc. Preferred Investment Option Shares: _______ Issue Date:______, 2022 Initial Exercise Date: _______, 2023 THIS PREFERRED INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above [SIX MONTHS FOLLOWING THE ISSUE DATE] and on or prior to 5:00 p.m. on ______________ [1] but not thereafter, to subscribe for and purchase from Nuvectis Pharma, Inc., a Delaware corporation , up to ______ shares of the Company’ s Common Stock. The purchase price of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Se...",
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT Nuvectis Pharma, Inc. Warrant Shares: _______ Issue Date:______, 2022 Initial Exercise Date: _______, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received,[ _____________ ] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Nuvectis Pharma, Inc., a Delaware corporation , up to [ ______] shares of the Company’ s Common Stock . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms...",
"SELLING SHAREHOLDERS The common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common stock and warrants, see “Private Placement of Common Shares and Warrants” above. We are registering the shares of common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past three years. The table below lists the selling shareholders and other information regarding the beneficial ownership of the s...",
"Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement July 27, 2022, Fort Lee, NJ - Nuvectis Pharma, Inc , a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, announced today that it has entered into definitive agreements with healthcare-focused institutional and accredited investors for the issuance and sale of 1,924,689 shares of common stock at a purchase price of $8.25 per share and preferred investment option. The investors also purchased preferred investment options to purchase up to an aggregate of 1,924,689 shares of common stock. The preferred investment options will have an exercise price of $9.65, will become exercisable commencing six months following date of issuance and..." |
|
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/28/2022 |
SC 13G/A
| Mosseri Marlio Charles reports a 11% stake in Nuvectis Pharma, Inc. |
| 03/28/2022 |
SC 13D
| BENTSUR RON reports a 21.5% stake in nuvectis pharma, inc. |
| 03/24/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/22/2022 |
8-K
| Quarterly results |
| 02/15/2022 |
SC 13G
| Mosseri Marlio Charles reports a 10% stake in Nuvectis Pharma, Inc. |
|
|
|